Oslo, 9 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, sold on 8 March 2024, 400,000 shares in the company at an average price of NOK 7.8984 per share. Following these transactions, Langøya Invest AS and closely related parties hold 400,000 shares in Ultimovacs ASA.
This information is subject to the disclosure requirements pursuant to the Market Abuse Regulation article 19 and section 5-12 of the Norwegian Securities Trading Act.
Attachment
New initiative will promote AI policies and solutions to transform American health careWASHINGTON, Jan. 12,…
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA…
GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader…
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in…
Preliminary, directional read of planned 88-investor sample indicates heightened proof thresholds (unit economics, reimbursement, outcomes)…
• Patient 1 of Cohort 1 has now completed the 24-month follow-up timepoint, and at…